Modality
mRNA
MOA
HER2
Target
IL-17A
Pathway
DDR
CML
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
Apr 2018
→ Jul 2029
Phase 1Current
NCT07080299
2,281 pts·CML
2021-12→2029-07·Terminated
NCT07777971
439 pts·CML
2018-04→2028-09·Active
2,720 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-09-052.4y awayPh2 Data· CML
2029-07-243.3y awayPh2 Data· CML
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Active
P1/2
Termina…
Catalysts
Ph2 Data
2028-09-05 · 2.4y away
CML
Ph2 Data
2029-07-24 · 3.3y away
CML
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07080299 | Phase 1/2 | CML | Terminated | 2281 | SeizFreq |
| NCT07777971 | Phase 1/2 | CML | Active | 439 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 |